This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Completed Pancreatic Cancer Phase 1-2 Trial Concluded The Encapsulated Cells Produced Chemotherapy That May Treat Downstream Micro Metastatic Disease

Nuvilex, Inc. (OTCQB: NVLX), an emerging biotechnology provider of cell and gene therapy solutions, discussed today the proprietary Cell-in-a-Box® technology, being acquired from SG Austria, that was used for the pancreatic cancer clinical trial and may have an effect on downstream micro metastatic disease.

The proprietary Cell-in-a-Box® technology capsules, when used in combination with cytochrome P450 expressing cells, can be placed at the tumor site so that the cells inside the capsule can convert the drug ifosfamide. When the patient is subsequently injected with the chemotherapeutic drug ifosfamide, the encapsulated cells transform this prodrug into its active form, which kills the pancreatic cancer cells.

It is extremely difficult to diagnose pancreatic cancer early on. Approximately 26% of people diagnosed have pancreatic cancer that spreads into the regions beside the tumor and 52% of patients have metastatic disease spread to regional lymph nodes and the liver. From trial and use data, for all pancreatic cancer stages combined there is only a 26% survival rate at 1 year, whereas using Cell-in-a-Box® technology in the phase 1/2 clinical trial the 1-year survival rate was 36%, double that of the standard Gemzar® therapy 1-year results of 18%.

The advantage of this approach is that pancreatic tumors are locally delivered high concentrations of active drug, allowing a decrease to only one-third of the standard amount of ifosfamide, reducing toxic side effects such as nausea, diarrhea, bone marrow suppression and weight loss. Due to the advanced stage most pancreatic cancers are found in, an important question has been whether the reduced amount of drug used can have an effect on the few pancreatic cancer cells, called micro metastases, which leave the primary tumor and are found in organs “downstream” from the original pancreatic tumor.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs